<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03596294</url>
  </required_header>
  <id_info>
    <org_study_id>ID-054-106</org_study_id>
    <secondary_id>2018-001607-36</secondary_id>
    <nct_id>NCT03596294</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Male Subjects to Investigate Whether Administration of Rifampicin Can Affect the Fate of Clazosentan in the Body of Clazosentan</brief_title>
  <official_title>A Single-center, Randomized, Double-blind, Two-period Cross-over Study to Investigate the Effect of Rifampicin on the Pharmacokinetics of Clazosentan in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study in healthy male subjects to investigate whether administration of rifampicin can
      affect the fate in the body (amount and time of presence in the blood) of clazosentan
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 19, 2018</start_date>
  <completion_date type="Actual">August 3, 2018</completion_date>
  <primary_completion_date type="Actual">August 3, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, two-period, cross-over Phase 1 study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC from zero to time t of the last measured concentration above the limit of quantification</measure>
    <time_frame>24 hours post treatment infusion initiation</time_frame>
    <description>The plasma PK parameters of clazosentan will be derived by non-compartmental analysis of the plasma concentration-time profiles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from zero to infinity (AUC0-inf)</measure>
    <time_frame>24 hours post treatment infusion initiation</time_frame>
    <description>The plasma PK parameters of clazosentan will be derived by non-compartmental analysis of the plasma concentration-time profiles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from zero to 3 h (AUC0-3)</measure>
    <time_frame>24 hours post treatment infusion initiation</time_frame>
    <description>The plasma PK parameters of clazosentan will be derived by non-compartmental analysis of the plasma concentration-time profiles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The maximum plasma concentration (Cmax)</measure>
    <time_frame>24 hours post treatment infusion initiation</time_frame>
    <description>The plasma PK parameters of clazosentan will be derived by non-compartmental analysis of the plasma concentration-time profiles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal half-life (tÂ½)</measure>
    <time_frame>24 hours post treatment infusion initiation</time_frame>
    <description>The plasma PK parameters of clazosentan will be derived by non-compartmental analysis of the plasma concentration-time profiles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total body clearance (CL)</measure>
    <time_frame>24 hours post treatment infusion initiation</time_frame>
    <description>The plasma PK parameters of clazosentan will be derived by non-compartmental analysis of the plasma concentration-time profiles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution at steady state (Vss)</measure>
    <time_frame>24 hours post treatment infusion initiation</time_frame>
    <description>The plasma PK parameters of clazosentan will be derived by non-compartmental analysis of the plasma concentration-time profiles</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Treatment sequence AB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period A:
Saline + clazosentan
Period B:
Rifampicin + clazosentan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence BA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period B:
Rifampicin + clazosentan
Period A:
Saline + clazosentan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clazosentan</intervention_name>
    <description>Continuous i.v. infusion of 15 mg/h of clazosentan for 3 h</description>
    <arm_group_label>Treatment sequence AB</arm_group_label>
    <arm_group_label>Treatment sequence BA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin</intervention_name>
    <description>Single i.v. dose of 600 mg rifampicin for 30 min</description>
    <arm_group_label>Treatment sequence AB</arm_group_label>
    <arm_group_label>Treatment sequence BA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline (0.9% sodium chloride)</intervention_name>
    <description>Single i.v infusion of 500 mL saline for 30 min</description>
    <arm_group_label>Treatment sequence AB</arm_group_label>
    <arm_group_label>Treatment sequence BA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent in a language understandable to the subject prior to any
             study-mandated procedure.

          -  Healthy male subjects aged between 18 and 65 years (inclusive) at Screening.

          -  Body mass index (BMI) of 18.0 to 30.0 kg/m2 (inclusive) at Screening.

          -  Systolic blood pressure (SBP) 100-145 mmHg, diastolic blood pressure (DBP) 50-90 mmHg,
             and pulse rate 45-90 bpm (inclusive), measured on the same arm, after 5 min in the
             supine position at Screening and on Day -1 of the first Period.

          -  Healthy on the basis of physical examination, cardiovascular assessments and
             laboratory tests.

        Study-specific criteria

        - Acceptance for the duration of the study and for 3 months thereafter to use a condom and
        not to procreate.

        Exclusion Criteria:

          -  Previous exposure to clazosentan.

          -  Previous exposure to rifampicin within 3 months prior to Screening.

          -  Known hypersensitivity to clazosentan or rifampicin or treatments of the same class,
             or any of their excipients.

          -  Known hypersensitivity or allergy to natural rubber latex.

          -  Participation in a clinical study involving study treatment administration within 3
             months prior to Screening or in more than 4 clinical studies within 1 year prior to
             Screening.

          -  History or clinical evidence of alcoholism or drug abuse within the 3-year period
             prior to Screening.

          -  Positive results for hepatitis B surface antigen or hepatitis C virus antibody at
             Screening.

          -  Positive results from the HIV serology at Screening.

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             full participation in the study or compliance with the protocol.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>QPS Netherlands B.V.</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>July 5, 2018</study_first_submitted>
  <study_first_submitted_qc>July 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2018</study_first_posted>
  <last_update_submitted>October 22, 2018</last_update_submitted>
  <last_update_submitted_qc>October 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

